The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now prescribed to millions of patients seeking significant weight loss. Yet a substantial number of physicians continue to prioritize lifestyle interventions as their primary approach, even as professional guidelines increasingly emphasize pharmacologic options and patients arrive with specific medication requests.

What drives this clinical philosophy in an era where injectable medications promise double-digit weight loss? The answer lies not in resistance to innovation but in a nuanced understanding of what produces lasting results in real-world practice.

Guidelines Support Combination Therapy, Not Medication Replacement

Current medical guidance reflects the growing eviden

See Full Page